Systematic reviews in paediatric multiple sclerosis and Creutzfeldt-Jakob disease exemplify shortcomings in methods used to evaluate therapies in rare conditions
暂无分享,去创建一个
Martin Posch | Sarah Zohar | Tim Friede | Nigel Stallard | Norbert Benda | Christian Röver | Steffen Unkel | T. Friede | M. Posch | N. Benda | N. Stallard | S. Zohar | C. Röver | S. Unkel
[1] F. Hanefeld,et al. Treatment of early onset multiple sclerosis with subcutaneous interferon beta-1a , 2005, Neurology.
[2] S. Senn. Controlled trials in single subjects. , 1991, BMJ.
[3] B. Wieseler,et al. Reporting a systematic review. , 2010, Chest.
[4] W. D. Ray. 4. Modelling Survival Data in Medical Research , 1995 .
[5] J. R. Scotti,et al. Available From , 1973 .
[6] J. Benito‐León. Compassionate use of quinacrine in Creutzfeldt–Jakob disease fails to show significant effects , 2005, Neurology.
[7] M. Rossor,et al. Safety and efficacy of quinacrine in human prion disease (PRION-1 study): a patient-preference trial , 2009, The Lancet Neurology.
[8] A. Kesselheim,et al. Strategies for Postmarketing Surveillance of Drugs for Rare Diseases , 2014, Clinical pharmacology and therapeutics.
[9] S. Tenembaum. Ethical challenges in paediatric clinical trials in multiple sclerosis , 2012, Therapeutic advances in neurological disorders.
[10] Jonathan J Deeks,et al. Chapter 13: Including non-randomized studies , 2008 .
[11] A. Ghezzi,et al. Subcutaneous Interferon Beta-1a in Pediatric Multiple Sclerosis , 2013, Journal of child neurology.
[12] Bykova Ov,et al. [The use of beta-interferon-1b in children and adolescents with multiple sclerosis]. , 2006 .
[13] T. Johannessen,et al. Controlled trials in single subjects. 1. Value in clinical medicine. , 1991, BMJ.
[14] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.
[15] N. Freemantle,et al. Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research , 2013, BMJ.
[16] D. Altman,et al. Chapter 8: Assessing risk of bias in included studies , 2008 .
[17] Joshua J Gagne,et al. Innovative research methods for studying treatments for rare diseases: methodological review , 2014, BMJ : British Medical Journal.
[18] S. Tenembaum,et al. Interferon beta-1a treatment in childhood and juvenile-onset multiple sclerosis , 2006, Neurology.
[19] M. Gobbi,et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial , 2014, The Lancet Neurology.
[20] Jeremy E. Oakley,et al. Uncertain Judgements: Eliciting Experts' Probabilities , 2006 .
[21] Steven N Goodman,et al. A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain-Barre , 2005, Clinical trials.
[22] Robert A Gross,et al. Levels of evidence , 2008, Neurology.
[23] Désirée van der Heijde,et al. Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial , 2013, The Lancet.
[24] D. Spiegelhalter,et al. Summarizing historical information on controls in clinical trials , 2010, Clinical trials.
[25] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.
[26] The Lancet Neurology. Rare neurological diseases: a united approach is needed. , 2011, The Lancet. Neurology.
[27] C. Pozzilli,et al. Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study , 2005, Multiple sclerosis.
[28] S. Suissa,et al. Effectiveness of early beta interferon on the first attack after confirmed multiple sclerosis: a comparative cohort study. , 2008, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.
[29] M. Sahraian,et al. Treatment of early onset multiple sclerosis with suboptimal dose of interferon beta-1a. , 2006, Neuropediatrics.
[30] Lauren B. Krupp,et al. Treatment of pediatric multiple sclerosis , 2005, Current treatment options in neurology.
[31] A. Ghezzi,et al. Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis , 2012, Multiple sclerosis.
[32] S. Day,et al. Sample size and power for comparing two or more treatment groups in clinical trials. , 1989, BMJ.
[33] Boris Freidlin,et al. Statistical Challenges in the Evaluation of Treatments for Small Patient Populations , 2013, Science Translational Medicine.
[34] Tim Friede,et al. Doxycycline in early CJD: a double-blinded randomised phase II and observational study , 2016, Journal of Neurology, Neurosurgery & Psychiatry.
[35] Nicky J Welton,et al. Evidence Synthesis for Decision Making in Healthcare , 2012 .
[36] Lisa V Hampson,et al. Bayesian methods for the design and interpretation of clinical trials in very rare diseases , 2014, Statistics in medicine.
[37] F. Tagliavini. S3-01-03: Prion therapy: Tetracyclic compounds in animal models and patients with Creutzfeldt-Jakob disease , 2008, Alzheimer's & Dementia.
[38] Tim Friede,et al. Safety and Efficacy of the ACE-Inhibitor Ramipril in Alport Syndrome: The Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III EARLY PRO-TECT Alport Trial in Pediatric Patients , 2012, ISRN pediatrics.
[39] A. Ghezzi,et al. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study , 2005, Neurological Sciences.
[40] M. Filippi,et al. Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases , 2013, Multiple sclerosis.
[41] D. Prayer,et al. Natalizumab therapy for highly active pediatric multiple sclerosis. , 2013, JAMA neurology.
[42] Alan Aldrich,et al. Designing and implementing sample and data collection for an international genetics study: the Type 1 Diabetes Genetics Consortium (T1DGC) , 2010, Clinical trials.
[43] E. Irle,et al. Efficacy of flupirtine on cognitive function in patients with CJD , 2004, Neurology.
[44] S. Prusiner,et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease , 2013, Neurology.
[45] J. Higgins. Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .
[46] C. Pozzilli,et al. Treatment of early-onset multiple sclerosis with intramuscular interferonβ-1a: long-term results , 2007, Neurological Sciences.
[47] E. Waubant,et al. Therapeutic advances in pediatric multiple sclerosis. , 2013, The Journal of pediatrics.
[48] Sylvie Chabaud,et al. Experimental designs for small randomised clinical trials: an algorithm for choice , 2013, Orphanet Journal of Rare Diseases.
[49] C. Pozzilli,et al. Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience , 2009, Neurological Sciences.
[50] M. A. Best. Bayesian Approaches to Clinical Trials and Health‐Care Evaluation , 2005 .
[51] Nicky J Welton,et al. Evidence Synthesis for Decision Making in Healthcare: Welton/Evidence Synthesis for Decision Making in Healthcare , 2012 .
[52] M. Freedman,et al. Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis , 2006, Neurology.
[53] B. Freidlin,et al. Outcome--adaptive randomization: is it useful? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[54] A R Jadad,et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.
[55] Ó. Zurriaga,et al. Rare diseases epidemiology research. , 2010, Advances in experimental medicine and biology.
[56] C. H. Evans,et al. Small clinical trials : issues and challenges , 2001 .